GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Interpace Biosciences Inc (OTCPK:IDXG) » Definitions » Equity-to-Asset

Interpace Biosciences (Interpace Biosciences) Equity-to-Asset : -4.74 (As of Dec. 2023)


View and export this data going back to 1998. Start your Free Trial

What is Interpace Biosciences Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Interpace Biosciences's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $-61.67 Mil. Interpace Biosciences's Total Assets for the quarter that ended in Dec. 2023 was $13.02 Mil. Therefore, Interpace Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 was -4.74.

The historical rank and industry rank for Interpace Biosciences's Equity-to-Asset or its related term are showing as below:

IDXG' s Equity-to-Asset Range Over the Past 10 Years
Min: -4.74   Med: 0.17   Max: 0.74
Current: -4.74

During the past 13 years, the highest Equity to Asset Ratio of Interpace Biosciences was 0.74. The lowest was -4.74. And the median was 0.17.

IDXG's Equity-to-Asset is ranked worse than
97.91% of 239 companies
in the Medical Diagnostics & Research industry
Industry Median: 0.58 vs IDXG: -4.74

Interpace Biosciences Equity-to-Asset Historical Data

The historical data trend for Interpace Biosciences's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Interpace Biosciences Equity-to-Asset Chart

Interpace Biosciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.42 -0.64 -1.10 -3.95 -4.74

Interpace Biosciences Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.95 -3.94 -3.90 -4.40 -4.74

Competitive Comparison of Interpace Biosciences's Equity-to-Asset

For the Diagnostics & Research subindustry, Interpace Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Interpace Biosciences's Equity-to-Asset Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Interpace Biosciences's Equity-to-Asset falls into.



Interpace Biosciences Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Interpace Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-61.672/13.021
=-4.74

Interpace Biosciences's Equity to Asset Ratio for the quarter that ended in Dec. 2023 is calculated as

Equity to Asset (Q: Dec. 2023 )=Total Stockholders Equity/Total Assets
=-61.672/13.021
=-4.74

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Interpace Biosciences  (OTCPK:IDXG) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Interpace Biosciences Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Interpace Biosciences's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Interpace Biosciences (Interpace Biosciences) Business Description

Traded in Other Exchanges
Address
300 Interpace Parkway, Morris Corporate Center 1, Building C, Parsippany, NJ, USA, 07054
Interpace Biosciences Inc is engaged in the life sciences industry. It provides molecular diagnostics, bioinformatics, and pathology services for the evaluation of the risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The company develops and commercializes genomic tests and related first-line assays principally focused on the early detection of patients with indeterminate biopsies and at high risk of cancer using the latest technology. It operates under one segment which is the business of developing and selling diagnostic clinical services.
Executives
Christopher Mccarthy officer: Principal Financial Officer C/O INTERPACE BIOSCIENCES, INC., 300 INTERPACE PARKWAY; BLDG C, 1ST FLOOR, PARSIPPANY NJ 07054
Vijay Aggarwal director 2320 SCIENTIFIC PARK DRIVE, WILMINGTON NC 28405
Thomas W. Burnell director, officer: President and CEO 1355 PEACHTREE STREET, SUITE 1150, ATLANTA GA 30309
Peter H Kamin 10 percent owner 2720 DONALD ROSS ROAD, #311, PALM BEACH GARDENS FL 33410
Fred S. Knechtel officer: Chief Financial Officer REMY INTERNATIONAL, INC., 600 CORPORATION DR., PENDLETON IN 46064
Fortunato R. Rocca director C/O EXAGEN INC., 1261 LIBERTY WAY, SUITE, VISTA CA 92081
Edward Chan director C/O 1315 CAPITAL II, L.P., 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
1315 Capital Ii, L.p. 10 percent owner 2929 WALNUT STREET, SUITE 1240, PHILADELPHIA PA 19104
Robert J. Gorman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Laurence Mccarthy director 2110 RUTHERFORD ROAD, CARLSBAD CA 92008
Ampersand 2018 Limited Partnership 10 percent owner 55 WILLIAM STREET, SUITE 240, WELLESLEY MA 02481
Eric B. Lev director, 10 percent owner C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, PARSIPPANY NJ 07054
Thomas John Freeburg officer: Chief Accounting Officer INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PKWY, BLDG. C, PARSIPPANY NJ 07054
Gregory Richard officer: Chief Commerical Officer C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054
Felice Schnoll-sussman director C/O INTERPACE DIAGNOSTICS GROUP, INC., 300 INTERPACE PARKWAY, BUILDING A, PARSIPPANY NJ 07054

Interpace Biosciences (Interpace Biosciences) Headlines

From GuruFocus

Interpace Biosciences Announces Path Forward in Letter to Shareholders

By GlobeNewswire GlobeNewswire 02-17-2021

Interpace Biosciences Announces Impending Delisting from Nasdaq

By Marketwired Marketwired 02-17-2021